John B. Briggs

John B. Briggs

Auto-generated profile, based on publicly available information

John B. Briggs

Genentech Inc

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RSRobert L. Shields
Robert L. Shields
ANAngela K. Namenuk
Angela K. Namenuk
KHKyu Hong
Kyu Hong
YMY. Gloria Meng
Y. Gloria Meng
JRJulie Rae
Julie Rae
LPLeonard G. Presta
Leonard G. Presta
Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated immune responses with cellular effector functions. A high resolution map of the binding site on human IgG1 for human FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, and FcRn receptors has been determined. A common set of IgG1 residues is involved in binding to all FcγR; FcγRII and FcγRIII also utilize residues outside this common set. In addition to residues which, when altered, abrogated binding to one or more of the receptors, several residues were found that improved binding only to specific receptors or simultaneously improved binding to one type of receptor and reduced binding to another type. Select IgG1 variants with improved binding to FcγRIIIA exhibited up to 100% enhancement in antibody-dependent cell cytotoxicity using human effector cells; these variants included changes at residues not found at the binding interface in the IgG/FcγRIIIA co-crystal structure (Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000)Nature 406, 267–273). These engineered antibodies may have important implications for improving antibody therapeutic efficacy.

1 May 2000 in Glycobiology
Verified
Journal Article
Open access
PDF file
TRT.Shantha Raju
T.Shantha Raju
JBJohn B. Briggs
John B. Briggs
SBSteve M. Borge
Steve M. Borge
AJAndrew J. S. Jones
Andrew J. S. Jones
Immunoglobulins (IgG) are soluble serum glycoproteins in which the oligosaccharides play significant roles in the bioactivity and pharmacokinetics. Recombinant immuno­globulins (rIgG) produced in different host cells by recombinant DNA technology are becoming major therapeutic agents to treat life threatening diseases such as cancer. Since glycosylation is cell type specific, rIgGs produced in different host cells contain different patterns of oligosaccharides which could affect the biological functions. In order to determine the extent of this variation N-linked oligosaccharide structures present in the IgGs of different animal species were characterized. IgGs of human, rhesus, dog, cow, guinea pig, sheep, goat, horse, rat, mouse, rabbit, cat, and chicken were treated with peptide-N-glycosidase-F (PNGase F) and the oligosaccharides analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for neutral and acidic oligosaccharides, in positive and negative ion modes, respectively. The data show that for neutral oligosaccharides, the proportions of terminal Gal, core Fuc and/or bisecting GlcNAc containing oligosaccharides vary from species to species; for sialylated oligosaccharides in the negative mode MALDI-TOF-MS show that human and chicken IgG contain oligosaccharides with N-acetylneuraminic acid (NANA), whereas rhesus, cow, sheep, goat, horse, and mouse IgGs contain oligosaccharides with N-glycolylneuraminic acid (NGNA). In contrast, IgGs from dog, guinea pig, rat, and rabbit contain both NANA and NGNA. Further, the PNGase F released oligosaccharides were derivatized with 9-aminopyrene 1,4,6-trisulfonic acid (APTS) and analyzed by capillary electrophoresis with laser induced fluorescence detection (CE-LIF). The CE-LIF results indicate that the proportion of the two isomers of monogalactosylated, biantennary, complex oligosaccharides vary significantly, suggesting that the branch specificity of β1,4-galactosyltransferase might be different in different species. These results show that the glycosylation of IgGs is species-specific, and reveal the necessity for appropriate cell line selection to express rIgGs for human therapy. The results of this study are useful for people working in the transgenic area.

1 November 1999 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
SWS. Weikert
S. Weikert
DPD. Papac
D. Papac
JBJ. Briggs
J. Briggs
DCD. Cowfer
D. Cowfer
STS. Tom
S. Tom
LKL. Krummen
L. Krummen

1 May 1998 in Glycobiology
Verified
Journal Article
Open access
PDF file
DPDamon I. Papac
Damon I. Papac
JBJohn B. Briggs
John B. Briggs
ECEdward T. Chin
Edward T. Chin
AJAndrew J.S. Jones
Andrew J.S. Jones
This report describes a convenient method for the rapid and efficient release of N-linked oligosaccharides from low microgram amounts of glycoproteins. A 96-well MultiScreen assay system containing a polyvinylidene difluoride (PVDF) membrane is employed to immobilize glycoproteins for subsequent enzymatic deglycosylation. Recombinant tissue-type plasminogen activator (rt-PA) is used to demonstrate the deglycosylation of 0.1–50 µg of a glycoprotein. This method enabled the recovery of a sufficient amount of N-linked oligosaccharides released enzymatically with peptide N-glycosidase F (PNGaseF) from as little as 0.5 µg rt-PA for subsequent analysis by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. The immobilization of rt-PA to the PVDF membrane did not sterically inhibit the PNGaseF-mediated release of oligosaccharides from rt-PA as determined by tryptic mapping experiments. Comparison of the oligosaccharides released from 50 µg of rt-PA by either the 96-well plate method or by a standard solution digestion procedure showed no significant differences in the profiles obtained by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD). Both neutral and sialylated oligosaccharide standards spiked into wells were recovered equally as determined by HPAEC-PAD. One advantage of this approach is that reduction and alkylation can be performed on submicrogram amounts of glycoproteins with easy removal of reagents prior to PNGaseF digestion. In addition, this method allows 60 glycoprotein samples to be deglycosylated in 1 day with MALDI-TOF or HPAEC-PAD analysis being performed on the following day.

1 July 2001 in Biochemistry
Verified
Journal Article
Closed access
TRT. Shantha Raju
T. Shantha Raju
JBJohn B. Briggs
John B. Briggs
SCSteven M. Chamow
Steven M. Chamow
MWMarjorie E. Winkler
Marjorie E. Winkler
AJAndrew J. S. Jones
Andrew J. S. Jones

1 June 2009 in Analytical Biochemistry
Verified
Journal Article
Closed access
JBJohn B. Briggs
John B. Briggs
RKRodney G. Keck
Rodney G. Keck
SMStacey Ma
Stacey Ma
WLWendy Lau
Wendy Lau
AJAndrew J.S. Jones
Andrew J.S. Jones